Key Points
- Organigram director James Hideo Yamanaka bought 20,000 shares on May 22 at an average price of C$1.10, totaling C$22,000. Following the purchase, he directly owned 20,000 shares.
- The stock opened at C$1.60, below its 50-day average of C$1.85 and 200-day average of C$2.07, with a market cap of C$225.24 million and a 12-month range of C$1.44 to C$3.09.
- Analysts currently rate Organigram a Buy overall, with a consensus price target of C$3.13. Recent calls include Canaccord Genuity’s C$3.00 target and ATB Cormark’s reduced target of C$3.25.
Organigram Holdings Inc. (TSE:OGI - Get Free Report) Director James Hideo Yamanaka bought 20,000 shares of the firm's stock in a transaction that occurred on Friday, May 22nd. The shares were purchased at an average cost of C$1.10 per share, with a total value of C$22,000.00. Following the transaction, the director directly owned 20,000 shares of the company's stock, valued at C$22,000. The trade was a ∞ increase in their ownership of the stock.
Organigram Price Performance
TSE OGI opened at C$1.60 on Tuesday. The firm's fifty day simple moving average is C$1.85 and its two-hundred day simple moving average is C$2.07. The company has a current ratio of 2.82, a quick ratio of 2.62 and a debt-to-equity ratio of 2.20. Organigram Holdings Inc. has a 12-month low of C$1.44 and a 12-month high of C$3.09. The firm has a market capitalization of C$225.24 million, a P/E ratio of -7.48, a P/E/G ratio of 0.42 and a beta of 1.72.
Analysts Set New Price Targets
A number of equities research analysts have commented on OGI shares. Canaccord Genuity Group set a C$3.00 price target on Organigram and gave the company a "buy" rating in a research note on Tuesday, January 27th. ATB Cormark Capital Markets downgraded shares of Organigram from a "strong-buy" rating to a "moderate buy" rating and cut their price objective for the company from C$3.50 to C$3.25 in a report on Wednesday, February 11th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, Organigram has a consensus rating of "Buy" and an average price target of C$3.13.
Check Out Our Latest Stock Analysis on OGI
About Organigram
(
Get Free Report)
Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
